Top

Published in:

Open Access 01-12-2015 | Letter to the Editor

Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response

Authors: Arpana Kamath, Ann M Joseph, Kumud Gupta, Digamber Behera, Anand Jaiswal, Ravindra Dewan, Maitreyi S Rajala

Published in: Experimental Hematology & Oncology | Issue 1/2015

Abstract

In view of the fact that certain non small cell lung carcinoma associated epidermal growth factor receptor mutations keep the receptor constitutively active, the downstream effectors of altered activity of mutant receptors are largely unknown. By 2D gel electrophoresis and MALDI-TOF/MS analysis, we showed that increased activity of EGFR mutants, L858R, L861Q and A871G induce heat shock proteins such as Hsp70, Hsp60, Hsp90B1, Hsp5a, Hsp71 and few transcriptional factors. Of which, Hsp70 was observed to be regulated more selectively to L861Q mutant. Our results suggest the possible role of heat shock proteins in lung tumor progression considering EGFR mutations.

Available only for authorised users

Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR –mutant in lung cancer in women and in East Asian populations: analysis of estrogen related polymorphism. Clin Cancer Res. 2008;14(13):4079–84.PubMedCentralPubMedCrossRef

Mehta J. Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population. Ind J Cancer. 2013;50(2):102–6.CrossRef

Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195–9.PubMedCrossRef

Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–9.PubMedCentralPubMedCrossRef

Pilot K, Zakowski MF, Fan PD, Sconfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors founding human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006;20(11):1496–510.CrossRef

Lynch TJ, Bell DW, Sordell R, Gurubhagavatulu S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib. New Eng J Med. 2004;350(21):2129–39.PubMedCrossRef

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response Gefitinib therapy. Science. 2004;304:1497–500.PubMedCrossRef

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med. 2005;352(8):786–92.PubMedCrossRef

Bloomston M, Zhou JX, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ. Fibrinogen gamma over expression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006;66(5):2592–9.PubMedCrossRef

10.

Lai KC, Liu CJ, Chang KW, Lee TC. Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells. Oncogene. 2013;32(32):3686–97.PubMedCrossRef

11.

Wang HX, Liu YF, Yang SJ, Duan CG, Wang YX, Zhao J, et al. Expression of HSP70 Grp94 and IgG in human lung carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24(5):447–9.PubMed

12.

Małusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas.An immunohistochemical study. Anticancer Res. 2001;21(2A):1015–21.PubMed

13.

Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: A multi-institutional case–control study. Clin Chim Acta. 2012;413:1115–20.PubMedCrossRef

14.

Li S, Wang R, Zhang M, Wang L, Cheng S. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J Surgical Oncol. 2013;11:173.CrossRef

Title: Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response
Authors: Arpana Kamath
Ann M Joseph
Kumud Gupta
Digamber Behera
Anand Jaiswal
Ravindra Dewan
Maitreyi S Rajala
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Experimental Hematology & Oncology / Issue 1/2015
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/s40164-015-0010-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Breast cancer brain metastases: the last frontier

Distinct genetic alterations in small cell carcinoma from different anatomic sites

Melanoma tumor growth is accelerated in a mouse model of sickle cell disease

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins

Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer